160 related articles for article (PubMed ID: 36435650)
1. Risk factors for breast cancer mortality after ductal carcinoma in situ diagnosis differ from those for invasive recurrence.
O'Keefe TJ; Chau H; Harismendy O; Wallace AM
Surgery; 2023 Feb; 173(2):305-311. PubMed ID: 36435650
[TBL] [Abstract][Full Text] [Related]
2. Treatment of ductal carcinoma in situ: an uncertain harm-benefit balance.
Prescrire Int; 2013 Dec; 22(144):298-303. PubMed ID: 24600734
[TBL] [Abstract][Full Text] [Related]
3. Recurrence following treatment of ductal carcinoma in situ with skin-sparing mastectomy and immediate breast reconstruction.
Spiegel AJ; Butler CE
Plast Reconstr Surg; 2003 Feb; 111(2):706-11. PubMed ID: 12560691
[TBL] [Abstract][Full Text] [Related]
4. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.
Narod SA; Iqbal J; Giannakeas V; Sopik V; Sun P
JAMA Oncol; 2015 Oct; 1(7):888-96. PubMed ID: 26291673
[TBL] [Abstract][Full Text] [Related]
5. Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ from 1990 to 2018 in England: population based cohort study.
Mannu GS; Wang Z; Dodwell D; Broggio J; Charman J; Darby SC
BMJ; 2024 Jan; 384():e075498. PubMed ID: 38267073
[TBL] [Abstract][Full Text] [Related]
6. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy.
Kerlikowske K; Molinaro A; Cha I; Ljung BM; Ernster VL; Stewart K; Chew K; Moore DH; Waldman F
J Natl Cancer Inst; 2003 Nov; 95(22):1692-702. PubMed ID: 14625260
[TBL] [Abstract][Full Text] [Related]
7. Benefit of adjuvant brachytherapy versus external beam radiation for early breast cancer: impact of patient stratification on breast preservation.
Smith GL; Jiang J; Buchholz TA; Xu Y; Hoffman KE; Giordano SH; Hunt KK; Smith BD
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):274-84. PubMed ID: 24268788
[TBL] [Abstract][Full Text] [Related]
8. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
9. HER2-Overexpressing Ductal Carcinoma
O'Keefe TJ; Blair SL; Hosseini A; Harismendy O; Wallace AM
Cancer Prev Res (Phila); 2020 Sep; 13(9):761-772. PubMed ID: 32493703
[TBL] [Abstract][Full Text] [Related]
10. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ.
Worni M; Akushevich I; Greenup R; Sarma D; Ryser MD; Myers ER; Hwang ES
J Natl Cancer Inst; 2015 Dec; 107(12):djv263. PubMed ID: 26424776
[TBL] [Abstract][Full Text] [Related]
11. Large and diffuse ductal carcinoma in situ: potentially lethal subtypes of "preinvasive" disease.
O'Keefe TJ; Harismendy O; Wallace AM
Int J Clin Oncol; 2022 Jan; 27(1):121-130. PubMed ID: 34618239
[TBL] [Abstract][Full Text] [Related]
12. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy.
Giannakeas V; Sopik V; Narod SA
JAMA Netw Open; 2018 Aug; 1(4):e181100. PubMed ID: 30646103
[TBL] [Abstract][Full Text] [Related]
13. Local Relapse After Breast-Conserving Therapy Versus Mastectomy for Extensive Pure Ductal Carcinoma In Situ ≥4 cm.
Hamilton SN; Nichol A; Wai E; Gondara L; Velásquez García HA; Speers C; Diocee R; Truong P
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):381-388. PubMed ID: 30253237
[TBL] [Abstract][Full Text] [Related]
14. Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion.
Mamtani A; Nakhlis F; Downs-Canner S; Zabor EC; Morrow M; King TA; Van Zee KJ
Ann Surg Oncol; 2019 Dec; 26(13):4264-4271. PubMed ID: 31440931
[TBL] [Abstract][Full Text] [Related]
15. Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years.
Subhedar P; Olcese C; Patil S; Morrow M; Van Zee KJ
Ann Surg Oncol; 2015 Oct; 22(10):3273-81. PubMed ID: 26215193
[TBL] [Abstract][Full Text] [Related]
16. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
17. Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.
Thompson AM; Clements K; Cheung S; Pinder SE; Lawrence G; Sawyer E; Kearins O; Ball GR; Tomlinson I; Hanby A; Thomas JSJ; Maxwell AJ; Wallis MG; Dodwell DJ;
Eur J Cancer; 2018 Sep; 101():210-219. PubMed ID: 30092498
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
Wapnir IL; Dignam JJ; Fisher B; Mamounas EP; Anderson SJ; Julian TB; Land SR; Margolese RG; Swain SM; Costantino JP; Wolmark N
J Natl Cancer Inst; 2011 Mar; 103(6):478-88. PubMed ID: 21398619
[TBL] [Abstract][Full Text] [Related]
19. Does intraductal breast cancer spread in a segmental distribution? An analysis of residual tumour burden following segmental mastectomy using tumour bed biopsies.
Jenkinson AD; Al-Mufti RA; Mohsen Y; Berry MJ; Wells C; Carpenter R
Eur J Surg Oncol; 2001 Feb; 27(1):21-5. PubMed ID: 11237487
[TBL] [Abstract][Full Text] [Related]
20. Comparison of local recurrence after mastectomy for pure ductal carcinoma
Kim D; Ki Y; Kim W; Park D; Joo J; Jeon H; Nam J
J Cancer Res Ther; 2020; 16(6):1197-1202. PubMed ID: 33342773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
